Gilead Sciences Inc GIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
-
FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
-
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
-
Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here.
-
Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
-
Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 — Data Talk
-
Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
-
Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
Trading Information
- Previous Close Price
- €130.52
- Day Range
- €130.88–130.88
- 52-Week Range
- —–134.58
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 1.24B
- Market Cap
- $162.29B
- Volume/Avg
- — / 776
Key Statistics
- Price/Earnings (Normalized)
- 18.12
- Price/Sales
- 6.26
- Dividend Yield (Trailing)
- 2.16%
- Dividend Yield (Forward)
- 2.20%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 2.74%
Company Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 17,000
- Website
- https://www.gilead.com
Competitors
Valuation
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.12 | 45.36 | 11.46 |
Price/Book Value | 15.68 | 8.57 | 3.98 |
Price/Sales | 6.26 | 5.43 | 2.13 |
Price/Cash Flow | 12.60 | 16.30 | 9.11 |
Price/Earnings
GIS
MRK
GSK
Financial Strength
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
Quick Ratio
GIS
MRK
GSK
Profitability
|
Metric
|
GIS
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
Return on Assets
GIS
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|Kvc!@y^c | LOCK|tr | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|R^k>@@ | LOCK|>& | $630B | |||
| AbbVie Inc
ABBV
| LOCK|z#@#>Rp | LOCK|BR | $489B | |||
| Merck & Co Inc
MRK
| LOCK|JsX@$&S | LOCK|^Ww | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|Y^!cqRF | LOCK|s> | $344B | |||
| Novartis AG ADR
NVS
| LOCK|<<&J&M@y | LOCK|%xm | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|#CL$r<b | LOCK|#&M | $246B | |||
| Amgen Inc
AMGN
| LOCK|Gy!!ckp | LOCK|#% | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|VfGjF&# | LOCK|w$ | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!?!mPf | LOCK|RBp | $169B |
United States